Structural and evolutionary analyses support reclassification of glycopeptide antibiotics as xyclopeptides

This study proposes reclassifying glycopeptide antibiotics into the broader class of xyclopeptides, subdivided into dalabactins (classical types I–IV) and murobactins (type V), based on structural and evolutionary analyses that reveal a fundamental divergence between these two groups.

The Gist

The Big Idea: Renaming a Messy Family

Imagine you have a huge family reunion. For decades, everyone has been calling the whole group "The Glycopeptides" because they all wear a similar style of jacket (they are peptides with sugar decorations).

However, the family has grown, and some distant cousins have shown up who look nothing like the rest. They don't wear the sugar jackets, they have different body shapes, and they do completely different jobs at the party. But because they are related, they've been forced into the same "Type V" box as the original family. This is causing confusion.

This paper says: "It's time to stop pretending they are all the same."

The authors propose a new family tree with a clear, unambiguous name for the whole group and two distinct sub-families.

---

The New Names

The authors are introducing a new umbrella term called Xyclopeptides. Think of this as the "Grand Family Name."

Inside this Grand Family, there are now two distinct branches:

1. The Dalabactins (The Old Guard):

   • Who they are: These are the classic "Glycopeptide Antibiotics" (like Vancomycin) that doctors have used for decades.
   • What they do: They act like a key that locks onto a specific door (a molecule called Lipid II) on the wall of bacteria, stopping them from building their cell walls.
   • Appearance: They are usually decorated with sugar "jewelry" (glycosylation).
   • The Analogy: They are the traditional, well-dressed members of the family who follow the old rules.

2. The Murobactins (The New Cousins):

   • Who they are: These are the compounds previously labeled "Type V."
   • What they do: They don't lock the door; instead, they act like a security guard that stops the bacteria's own demolition crew (autolysins) from tearing down the cell wall during repairs.
   • Appearance: They usually lack the sugar decorations and have different body shapes.
   • The Analogy: They are the rebellious cousins who dress differently and work a different shift, even though they share the same DNA.

---

How Did They Figure This Out?

The scientists didn't just guess; they used three different "detective tools" to prove these two groups are actually quite different.

1. The "Fingerprint" Match (Chemical Structure)

Imagine taking a photo of every family member's face and running them through a facial recognition app.

• The Result: The Dalabactins all look very similar to each other (like siblings). The Murobactins look like a completely different group of people. When you put them on a map, they form two separate islands with no bridges connecting them. This proves they are chemically distinct.

2. The "Blueprint" Check (Genomics)

Every family member has a blueprint (DNA) that tells them how to build their body. The scientists looked at the blueprints for the factories that make these drugs.

• The Result: The Dalabactins use a very specific, standard set of instructions. The Murobactins use a different set of instructions entirely. They are missing the "sugar decoration" instructions and have extra "security guard" instructions. It's like comparing a bakery that only makes bagels to a bakery that only makes donuts; even if they are both bakeries, the machines and recipes are totally different.

3. The "Family Tree" (Evolution)

They built a giant family tree based on the DNA of the bacteria that make these drugs.

• The Result: The tree showed a deep split. The Dalabactins branch off one way, and the Murobactins branch off a completely different way, millions of years ago. They are distant relatives, not immediate siblings.

---

Why Does This Matter?

You might ask, "Why change the names? It's just a label."

The authors argue that names matter because they tell a story.

• Confusion: If you call a Murobactin a "Glycopeptide," a scientist might assume it has sugar on it or works like Vancomycin. They might be wrong, and that could lead to failed experiments or missed opportunities for new medicines.
• Discovery: By giving the Murobactins their own name, scientists can now say, "We are looking for more Murobactins," and know exactly what kind of DNA and chemical structure to look for. It helps them find new drugs faster.

The Takeaway

This paper is like a librarian realizing that the "Science Fiction" section is too crowded and confusing. So, they decide to split it into two clear sections: "Space Opera" and "Cyberpunk."

• Old System: Everything is just "Glycopeptide."
• New System:
  • Xyclopeptides (The whole library).
  • Dalabactins (The Space Opera section: Classic, sugar-decorated, Lipid II blockers).
  • Murobactins (The Cyberpunk section: Sugar-free, autolysin blockers, structurally unique).

This new system makes it easier for scientists to understand the family, find new members, and develop better medicines to fight superbugs.

Technical Summary

1. Problem Statement

The classification of glycopeptide antibiotics (GPAs) has become increasingly ambiguous and biologically inaccurate. Historically, GPAs were categorized into Types I–V based on chemical features. However, recent discoveries, particularly of "Type V" compounds, have revealed significant divergences from the classical GPA paradigm:

• Structural Differences: Type V compounds often lack glycosylation, possess variable peptide backbone lengths (up to 9 amino acids vs. the canonical 7), and feature distinct crosslinking motifs (e.g., Trp-Hpg).
• Mechanistic Differences: While classical GPAs (Types I–IV) bind lipid II to inhibit cell wall synthesis, Type V compounds often inhibit autolysins involved in peptidoglycan remodeling.
• Nomenclature Confusion: The term "glycopeptide" is chemically broad (referring to any glycosylated peptide) and fails to capture the specific biosynthetic logic (non-ribosomal peptide synthesis with oxidative crosslinking) shared by these antibiotics. Previous attempts to rename them (e.g., "dalbaheptides") failed to gain traction.

The authors argue that the current Type I–V framework obscures the fundamental evolutionary and biosynthetic split between classical lipid II-binding agents and the newer, structurally distinct Type V agents.

2. Methodology

The study employed a multi-omics approach integrating chemical, genomic, and evolutionary analyses to validate a new classification framework.

• Dataset Curation:
  • Assembled a curated dataset of 182 biosynthetic gene clusters (BGCs) from at least nine bacterial genera.
  • Used antiSMASH for initial detection and BiG-SCAPE for grouping into Gene Cluster Families (GCFs).
  • Performed manual boundary refinement to remove unrelated flanking regions and ensure orthology accuracy.
  • Included resequencing of a Streptomyces varsoviensis strain to resolve an incomplete assembly.
• Structural Similarity Analysis:
  • Generated a Tanimoto similarity network using PubChem fingerprints of known xyclopeptide structures.
  • Visualized using Cytoscape to assess chemical distance independent of genomic data.
• Phylogenetic and Genomic Analysis:
  • Orthology Inference: Used zol to infer fine-grained orthologous groups, followed by phylogeny-guided curation for ambiguous cases (e.g., P450 enzymes).
  • Domain-Level Phylogeny: Analyzed Non-Ribosomal Peptide Synthetase (NRPS) genes at the domain level (rather than full-length) to account for frequent module rearrangements.
  • Network Reconstruction: Constructed a super network (using SplitsTree) from 47 individual gene/domain trees to visualize evolutionary relationships and incompatibilities.
  • Concatenated Phylogeny: Built a maximum-likelihood tree using 11 conserved genes/domains present in >90% of BGCs that passed a congruence filter.
• Backbone Prediction: Predicted peptide backbones from NRPS adenylation (A) domain specificity codes to correlate genomic architecture with chemical structure.

3. Key Contributions

The authors propose a new, biologically grounded nomenclature and classification system:

• Umbrella Term: Xyclopeptides. This term reflects the defining features of the class: a conformationally constrained ("macrocyclic-like") peptide core generated by oxidative crosslinking and the presence of a distinctive NRPS-associated X-domain (which recruits P450 enzymes for crosslinking).
• Subclass 1: Dalabactins (Legacy Types I–IV).
  • Characteristics: Typically 7-amino acid backbones, heavily glycosylated, contain Dpg (3,5-dihydroxyphenylglycine), and bind the D-Ala–D-Ala terminus of lipid II.
  • Biosynthetic Logic: Enriched in glycosylation and resistance genes.
• Subclass 2: Murobactins (Legacy Type V).
  • Characteristics: Variable backbone lengths (7–10 AA), often lack glycosylation, feature Trp-Hpg crosslinks, and target peptidoglycan remodeling (autolysins) rather than lipid II.
  • Biosynthetic Logic: Lack canonical glycosylation/resistance genes; enriched in regulatory and transport features.
• Refined Murobactin Classification: Proposed a provisional Type A–E subdivision for murobactins based on phylogenetic subclades and specific backbone motifs (e.g., Type A: Kistamicin-like; Type C: GP6738-like with 9 residues).

4. Key Results

• Structural Separation: The Tanimoto similarity network revealed a clear, distinct separation between dalabactins (forming a connected cluster) and murobactins (forming a separate, more diverse cluster). Murobactins showed limited similarity to dalabactins, confirming they are not merely peripheral extensions of the classical GPA structure.
• Evolutionary Divergence:
  • Phylogenetic networks and concatenated trees consistently recovered a deep split between dalabactins and murobactins.
  • Dalabactins formed a compact, monophyletic group, whereas murobactins spanned a broader phylogenetic space, reflecting greater evolutionary diversity in NRPS architecture.
• Genomic Signatures:
  • Dalabactins: Consistently enriched in glycosylation-related genes and resistance determinants.
  • Murobactins: Generally lack glycosylation genes. They exhibit unique domain architectures (e.g., expanded E-domains, TIGR01720 domains) and specific regulatory cassettes (e.g., VanR/VanS systems in Type C).
  • Type-Specific Markers: The study identified diagnostic gene patterns for each murobactin type (A–E), such as the presence of specific P450s in Type A and unique transporter/regulator sets in Type D.
• Validation of Legacy Types: Within the dalabactin subclass, the legacy Types I–IV were largely recovered as coherent subclades, validating the retention of these labels for practical use, despite some intermixing between Types III and IV due to sugar acylation similarities.

5. Significance

• Resolution of Nomenclature Ambiguity: The shift from "glycopeptide antibiotics" to "xyclopeptides" resolves the confusion caused by the broad chemical definition of glycopeptides. It aligns the name with the specific biosynthetic mechanism (oxidative crosslinking via X-domains).
• Biosynthetic and Functional Clarity: By separating dalabactins (lipid II binders) from murobactins (autolysin inhibitors), the new framework accurately reflects the distinct mechanisms of action and evolutionary trajectories of these compounds.
• Framework for Future Discovery: The proposed classification is scalable. The subdivision of murobactins into Types A–E provides a working hypothesis for classifying newly discovered compounds that lack known structures, guiding future genomic mining and chemical characterization.
• Community Consensus Model: The paper advocates for a collaborative, cross-disciplinary approach to natural product nomenclature, similar to the RiPP (Ribosomally synthesized and Post-translationally modified Peptide) field, to ensure terminology remains stable and biologically meaningful as discovery accelerates.

In conclusion, this study provides robust structural and evolutionary evidence that the historical "Type V" GPAs constitute a distinct evolutionary lineage. The proposed xyclopeptide framework offers a precise, unambiguous, and expandable taxonomy essential for the future development and regulation of these critical antimicrobial agents.